Thalidomide induces mucosal healing in Crohn's disease: Case report

Márcio Rios Leite, Sandra Sousa Santos, André Castro Lyra, Jaciane Mota, Genoile Oliveira Santana

INTRODUCTION

Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that is defined by relapsing and remitting episodes[1]. The inflammatory process is characterized by increased production of proinflammatory cytokines[2]. Tumor necrosis factor alpha (TNF-α) plays a central role in the pathogenesis of the disease[3].

Over the past few decades, medical therapy for CD has progressed significantly with immunomodulating agents such as azathioprine, 6-mercaptopurine, methotrexate, tacrolimus and cyclosporin, and biological agents such as infliximab, adalimumab and certolizumab[4]. Nevertheless, the use of biological therapies has been associated with an increased incidence of infections, especially...
infection by *Mycobacterium tuberculosis* (*Mtb*)\(^6\).

Thalidomide is an oral immunomodulatory agent with anti-TNF-\(\alpha\) properties\(^5,8\). Thalidomide increases the IFN-\(\gamma\) level and modulates several other cytokines as well, especially interleukin (IL)-2 and IL-12\(^2\). Recently, an open-label trial assessing the treatment of refractory CD reported response rates of 64% and 70% after a 12-wk course of thalidomide\(^7,9\).

Thalidomide costimulates T lymphocytes, with greater effect on CD8+ than on CD4+ T cells, which contributes to the protective immune response to *Mtb* infection\(^1,8\). Results from four case reports, one clinical trial and one placebo-controlled trial suggest the use of thalidomide for central nervous system tuberculosis (TB) not responding to standard therapy is beneficial. Thalidomide should not be used for routine treatment, but it may be useful as a “salvage therapy” in patients with tuberculosis meningitides and tuberculomas that are not responding to anti-TB drugs or to high-dose corticosteroids\(^11\).

We present the case of a 24-year-old CD patient, with gastric, ileal, colon and rectum involvement, as well as steroid dependency, which progressed with diminished response to infliximab after three years of therapy. A thoracic computed tomography scan revealed a pulmonary nodule suspected to be *Mtb* infection. He was started on thalidomide therapy and exhibited an excellent response.

## CASE REPORT

A 24-year-old male was first diagnosed with CD at the age of 10 when he presented fever, arthralgia of large joints (knees and ankles), bloody diarrhea (more than 10 bowel movements/d) and a Harvey-Bradshaw Index of 13. Endoscopy showed involvement of gastric corpus, ileum and all segments of the colon and rectum.

Initially, he was prescribed 1 mg/kg per day steroid, 100 mg/d azathioprine and 2.5 g/d sulfasalazine by a pediatric gastroenterologist. After eight years, he presented signs of active inflammatory bowel disease, with imaging revealing CD activity in gastric tissue, ileal tissue, and all segments of the colon and rectum (Harvey-Bradshaw Index 15). He was started on therapy with infliximab 5 mg/kg and continued on 100 mg/d azathioprine. After 2 mo, the patient presented significant clinical improvement with reduced stool frequency of 3 bowel movements/d and remission of joint inflammation. Endoscopic evaluation showed reduction of inflammatory disease activity in all segments of the colon and rectum, as well as healing of gastric lesions. The Harvey-Bradshaw Index was 4 after infliximab treatment.

Six months after the first dose of infliximab, the patient relapsed with bloody diarrhea in 6-8 bowel movements/d and a Harvey-Bradshaw Index of 12. The infliximab dose was increased to 10 mg/kg, which controlled the disease activity and led to a Harvey-Bradshaw index of 2. After 3 years, the patient presented with worsening of disease. Imaging studies revealed inflammatory activity in the gastric body, sigmoid and descending colon (Figure 1A). Infliximab was discontinued, and the azathioprine dose was increased to 150 mg/d in combination with mesalazine 1.2 g/d. We opted not to introduce adalimumab due to the presence of a cavitary pulmonary nodule in the left upper lobe measuring 0.6 × 0.8 cm\(^2\) (Figure 2A). At that time, we suspected infectious pneumonia (fungal/mycobacterial), eosinophilic granuloma or vasculitis. As the lung nodule was not accessible to percutaneous or bronchoscopy biopsy, we opted for a conservative approach. Because we did not have a definitive diagnosis of pulmonary disease and because the patient presented with all the symptoms of inflammatory bowel disease, including diarrhea, abdominal pain, weight loss, arthralgia and a Harvey-Bradshaw Index of 15, we opted to introduce thalidomide.

Thalidomide was started at 100 mg/d, and the patient's symptoms resolved, with initial improvement of abdominal pain and diarrhea between 1 and 4 mo (Harvey-Bradshaw Index 8) and complete remission of symptoms at 6 mo of therapy (Harvey-Bradshaw Index 3). The patient was asymptomatic, presenting 2-3 regular bowel movements/d and pasty stools, without blood or mucus. He denied abdominal pain, nausea and vomiting and complained of neuropathy. His weight increased by 10 kg. Laboratory tests showed normal inflammatory activity (CRP 3; ESR 2). Colonoscopy revealed scar tissue in sigmoid colon, descending, transverse, and ascending colon; and cecum; the ileocecal valve and terminal ileum showed ulceration, with thick fibrin interspersed with normal mucosa (Figure 1B). Control computerized tomography showed small (0.5 cm) calcified pulmonary nodules in the
apico-posterior segment, which were suggestive of primary Mtb infection (Figure 2B).

**DISCUSSION**

Standard therapies for inflammatory bowel disease fail to induce remission in about 30% of patients. Recent studies have suggested that thalidomide at doses varying from 50 to 300 mg/d is effective in refractory luminal and fistulizing CD. The response appears to be fairly rapid, and the remission rate is 20%-40% after 12 wk of thalidomide therapy.

Considering the present case, a patient with long-standing CD with extensive involvement of the digestive tract who failed to respond to infliximab after 3 years of therapy and had a pulmonary nodule possibly resulting from *Mycobacterium tuberculosis*, it was necessary to offer an effective and safe therapy to avoid infection. New therapies are needed in the context of patients with inflammatory bowel disease and tuberculosis diagnosed or suspected before or after biological treatment. Thalidomide appears to be a good option in this situation, as in selected cases of Mtb infection of the central nervous system.

Wettstein and Meagher were the first authors to describe thalidomide therapy in a woman with complicated CD. The patient was treated with all of the current medications at the time, including total parenteral nutrition, metronidazole and cyclosporine, without success. Resolution of the disease was achieved using 300 mg thalidomide per day and maintenance of 100 mg per day until the date of publication of the case. Vasiliauskas et al published an open-label trial that evaluated the tolerance and efficacy of low dose thalidomide for the treatment of moderate to severe steroid-dependent CD in 12 males with CDAI ≥ 250 and ≤ 500. The patients were treated with thalidomide 50 mg/d during the first 6 mo, increasing to 100 mg/d until the completion of 1 year of treatment. Disease activity (CDAI) improved consistently in all patients during the first 4 wk, with a response rate of 58% and a remission rate of 17%. After 12 mo, 70% of patients had responded, and 20% achieved remission. All patients were able to reduce steroid dosage to less than 50% of the initial dose; 48% of patients discontinued the use of steroids. Our patient also used low doses of thalidomide and is still in remission after 2 years of therapy without adverse events, which demonstrates that low doses of thalidomide appear to be well tolerated and effective over a period exceeding 12 wk.

Ehrenpreis et al reported an open-label trial of 22 patients with refractory CD (CDAI > 200 and/or perianal disease) treated with thalidomide 200 mg/d (18 patients) or 300 mg/d (4 patients). Nine patients with luminal disease and 13 with fistulas were included. Sixteen patients completed 4 wk of treatment (12 clinical responses, 4 remissions). Of the patients who completed 12 wk of treatment, 14 met the criteria for clinical response, nine achieved remission. Mean CDAI before and after treatment was 371 (95-468) and 175 (30-468), respectively (P < 0.001). Of note, none of these previous studies described the results of thalidomide usage after a long period of treatment. We describe here the case report of a 24-year-old male maintained on thalidomide therapy for more than 2 years without loss of response.

Bariol et al evaluated the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. Eleven patients (6 with CD, 4 with UC and 1 with indeterminate colitis) were treated with thalidomide 100 mg/d for 12 wk. Two patients were withdrawn from therapy after three weeks because of mood disorders. Of the remaining 9 patients, 8 responded to treatment (5 DC, 2 UC and 1 IC). The frequency of stools fell from 4.3 to 2.3 per day (P = 0.0012); stool consistency improved from 2.1 to 1.2 (P = 0.02); and mean CDAI decreased from 117 to 48 (P = 0.0008). Endoscopic inflammation, histological inflammation, CRP and ESR decreased significantly (P = 0.011, P = 0.03, P = 0.023 and P = 0.044, respectively). However, levels of serum TNF-α did not change. Thalidomide acts partly by accelerating the degradation of TNF-α mRNA, resulting in decreased production of this cytokine by activated mononuclear cells. It has also been shown to inhibit NF-κB activation, thus suppressing transcription of other important inflammatory cytokines, such as IL-12 both in vitro and in vivo. Thalidomide increases expression of the Th2-type cytokine IL-4 and decreases the helper to suppress T-cell ratio, effects that are likely to contribute to its efficacy in CD. Furthermore,
it has been shown to interfere with angiogenesis and to
downregulate cell adhesion molecules such as intercellu-
lar adhesion molecule-1 (ICAM-1), thought to be impor-
tant in lymphocyte homing mechanisms in inflammatory bowel disease. These multiple alternative mechanisms of action may be involved in thalidomide’s effectiveness in patients with severe disease refractory to conventional and biological agents, as was the case for the patient presented in this report.

Kane et al. reported a series of cases where thalido-
mide was a “salvage” therapy for patients with delayed hypersensitivity to infliximab. Four patients (two with ac-
tive luminal disease and two with fistulizing disease) were treated with thalidomide 200 mg/d and were evaluated monthly for 12 wk. One patient with a single perianal fistu-
sla had complete closure, and another had improvement in five perianal fistulas in 4 wk and closure in 12 wk. One
patient had a CDAI decrease of 250 points in 4 wk. One
patient was withdrawn from the study because of seda-
tion after the first week of treatment. Reported side ef-
effects were sedation (4/4), hypertension (1/4) and periph-
eral neuropathy (1/4). Due to thalidomide’s toxicity it is
recommended only in selected cases of refractory CD,
as in our patient, when the benefits outweigh the risk of peripheral neuropathy, and there is strict and full adher-
tance to the program of birth control, avoiding the risk of teratogenicity.

To our knowledge, this is the first case report of a
patient presenting with a pulmonary nodule who could be M. tuberculosis infection who was treated with thalidomide to control severe CD after loss of response to biological therapy, with a favorable evolution. Therefore, thalido-
mide might be considered a therapeutic option in similar clinical situations.

REFERENCES
1 Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn’s disease. Experience with 1379 pa-
2 MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma pro-
duction measured at the single cell level in normal and in-
3 van Dullemen HM, van Deventer SJ, Hommes DW, Bijl
4 Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica

J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis
associated with infliximab, a tumor necrosis factor alpha-
5 Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet
2004; 363: 1802-1811
6 Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thal-
idomide selectively inhibits tumor necrosis factor alpha pro-
173: 699-703
7 Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer
SB. Thalidomide therapy for patients with refractory Crohn’s
disease: an open-label trial. Gastroenterology 1999; 117:
1271-1277
8 Vasilioukas EA, Kam LY, Abreu-Martin MT, Hassard PV,
Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label
117: 1278-1287
9 Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide
11 Buononsenso D, Serranti D, Valentini P. Management of cen-
12 van Deventer SJ. Small therapeutic molecules for the treat-
ment of inflammatory bowel disease. Gut 2002; 50 Suppl 3:
III47-III53
13 Corral LG, Kaplan G. Immunomodulation by thalidomide
and thalidomide analogues. Ann Rheum Dis 1999; 58 Suppl 1:
I107-I113
14 Wettstein AR, Meagher AP. Thalidomide in Crohn’s disease.
Lancet 1997; 350: 1445-1446
15 Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD,
16 Bauditz J, Wodel S, Lochs H. Thalidomide reduces tumour
necrosis factor alpha and interleukin 12 production in pa-
tients with chronic active Crohn’s disease. Gut 2002; 50:
196-200
17 Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS. Inhibi-
tion of NF-kappa B activity by thalidomide through sup-
pression of IkappaB kinase activity. J Biol Chem 2001; 276:
22382-22387
18 Korzenik JR. Crohn’s disease: future anti-tumor necrosis
factor therapies beyond infliximab. Gastroenterol Clin North
Am 2004; 33: 285-301, ix
19 Bousvaros A, Mueller B. Thalidomide in gastrointestinal dis-
orders. Drugs 2001; 61: 777-787
20 Kane S, Stone LJ, Ehrenpreis E. Thalidomide as “salvage”
149-150

S-Editor Tian L  L-Editor Webster JR  E-Editor Zhang DN